2-氯-3-甲氧基硼酸频哪醇酯 | 1151564-03-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-氯-3-甲氧基硼酸频哪醇酯
• 中文别名: 2-氯-3-甲氧基苯硼酸频哪醇酯
• 英文名称: (2-chloro-3-methoxyphenyl)boronic acid pinacol ester
• 英文别名: 2-(2-chloro-3-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane；2-(2-Chloro-3-methoxyphenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
• CAS: 1151564-03-2
• 化学式: C₁₃H₁₈BClO₃
• 分子量: 268.548
• InChiKey: CVPMKYBFBINSHI-UHFFFAOYSA-N

物化性质

• 沸点：
  356.8±32.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.65
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 2–8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(2-Chloro-3-methoxyphenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(2-Chloro-3-methoxyphenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
CAS number: 1151564-03-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H18BClO3
Molecular weight: 268.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-3-甲氧基硼酸频哪醇酯 、 1-[2-氟-6-(三氟甲基)苄基]-5-碘-6-甲基嘧啶-2,4(1h,3h)-二酮 在 tris-(dibenzylideneacetone)dipalladium(0) 、 tri tert-butylphosphoniumtetrafluoroborate sodium hydroxide 、 溶剂黄146 、 N-乙酰基-L-半胱氨酸 作用下， 以 四氢呋喃 、 水 、 乙醇 为溶剂， 反应 4.25h， 以70%的产率得到5-(2-chloro-3-methoxy-phenyl)-1-(2-fluoro-6-trifluoromethyl-benzyl)-6-methyl-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  [EN] PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES
  [FR] PROCÉDÉS DE PRÉPARATION DE DÉRIVÉS D'URACILE

  摘要：

  本发明涉及制备促性腺激素释放激素（GnRH）受体拮抗剂结构（VI）的过程和中间体，以及其立体异构体和药用盐。

  公开号：

  WO2009062087A1
• 作为产物：
  描述：

  2-氯-3-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)-苯酚 、 硫酸二甲酯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.67h， 以85%的产率得到2-氯-3-甲氧基硼酸频哪醇酯
  参考文献：
  名称：

  [EN] PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES
  [FR] PROCÉDÉS DE PRÉPARATION DE DÉRIVÉS D'URACILE

  摘要：

  本发明涉及制备促性腺激素释放激素（GnRH）受体拮抗剂结构（VI）的过程和中间体，以及其立体异构体和药用盐。

  公开号：

  WO2009062087A1

文献信息

• NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7
  申请人：Pragma Therapeutics

  公开号：EP3459939A1

  公开（公告）日：2019-03-27

  The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (mGluR), preferably of the metabotropic glutamate receptor subtype 7 ("mGluR7"). The present invention also relates to pharmaceutical composition comprising such compound and their use for the treatment of prevention of disorders associated with glutamate dysfunction.

  本发明涉及新颖的杂环化合物。该发明还涉及调节代谢型谷氨酸受体（mGluR）的化合物，优选是代谢型谷氨酸受体亚型7（"mGluR7"）。本发明还涉及包含这种化合物的药物组合物及其用于治疗或预防与谷氨酸功能障碍相关的疾病的用途。
• [EN] INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE<br/>[FR] INHIBITEURS DE LA FORME INDUCTIBLE DE LA 6-PHOSPHOFRUCTOSE-2-KINASE
  申请人：EXELIXIS INC

  公开号：WO2012149528A1

  公开（公告）日：2012-11-01

  The invention is directed to inhibitors of inducible form of 6-phosphofructose-2-kinase of formula I, as well as to pharmaceutically acceptable salts of formula I, and pharmaceutical compositions comprising a compound of formula I. The compounds can be used to treat cancer.

  该发明涉及公式I的可诱导形式6-磷酸果糖-2-激酶的抑制剂，以及公式I的药用可接受盐，以及包含公式I化合物的药物组合物。这些化合物可用于治疗癌症。
• PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES
  申请人：Gallagher Donald J.

  公开号：US20110098472A1

  公开（公告）日：2011-04-28

  The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.

  本发明涉及用于制备GnRH受体拮抗剂的过程和中间体，其结构为（VI）；以及其立体异构体和药学上可接受的盐。
• Processes for the preparation of uracil derivatives
  申请人：Gallagher Donald J.

  公开号：US08765948B2

  公开（公告）日：2014-07-01

  The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.

  本发明涉及制备GnRH受体拮抗剂的过程和中间体，其结构为(VI)；以及其立体异构体和药物可接受的盐。
• [EN] COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE<br/>[FR] COMPOSÉS INTERAGISSANT AVEC DES PROTÉINES DE LA SUPERFAMILLE RAS POUR LE TRAITEMENT DE CANCERS, DE MALADIES INFLAMMATOIRES, DE RASOPATHIES ET D'UNE MALADIE FIBROTIQUE
  申请人：[en]SHY THERAPEUTICS, LLC

  公开号：WO2023196975A1

  公开（公告）日：2023-10-12

  Provided herein are compounds of Formula (I), or a pharmaceutically acceptable form thereof, and pharmaceutical compositions comprising the same. Also provided herein methods of modulating the activity of cellular targets by administering to a subject a compound of Formula (I), or a pharmaceutically acceptable form thereof. Further provided herein are methods of treating cancer, fibrotic diseases, and inflammatory diseases by administering to a subject a compound of or a pharmaceutically acceptable form thereof.